RxDoctor Payments Data

Ingrid Trenkle, MD

Dermatology · Redlands, CANPI 1629161260

Payments from drug & device makers

$29,400in general payments, 2019–2025

Across 735 payments — averaging $40.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$6K
  • Pfizer$4K
  • AbbVie$2K
  • LEO Pharma Inc.$2K
  • Biofrontera Inc.$2K
  • Sanofi$1K
  • plus $11K from 38 others

What the payments were for

  • Speaking & faculty fees$7,73426%
  • Travel & lodging$650%
  • Food & beverage$21,30572%
  • Education$2971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,400 in reported general payments places this provider in the 85th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$622,772
Medicare patients
985
Services billed
25,738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab31$113,801
Cosentyx Sensoready (2 Pens)Secukinumab11$94,783
CibinqoAbrocitinib12$67,360
VtamaTapinarof18$25,356
ZoryveRoflumilast21$17,234
JubliaEfinaconazole14$10,154
Imiquimod122$4,083
Clobetasol Propionate71$2,288
Minoxidil147$1,951
Doxycycline Hyclate73$1,781
Ketoconazole114$1,692
Tretinoin16$1,606
Fluorouracil24$1,333
Clindamycin Phosphate13$1,221
Metronidazole13$1,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerCibinqo$4,309$67,36012 claims
Dermavant Sciences, Inc.Vtama$587$25,35618 claims
Arcutis Biotherapeutics, Inc.Zoryve$668$17,23421 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$181$10,15414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,875 dermatology providers in California.

Other dermatology in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →